Nanotechnology Approaches for Mitigating Biologic Immunogenicity: A Literature Review

Area of Science:

• Immunology
• Biotechnology
• Nanotechnology

Background:

• Biologic therapeutics, especially monoclonal antibodies (mAbs), have transformed medicine.
• Immunogenicity, the induction of anti-drug antibodies (ADAs), frequently limits their clinical success.
• ADAs can decrease drug efficacy, alter pharmacokinetics, and cause adverse events.

Purpose of the Study:

• To review the mechanisms of ADA formation against biologic drugs.
• To explore nanotechnology-based strategies for reducing immunogenicity.
• To enhance the therapeutic potential and safety of biologics.

Main Methods:

• Review of existing literature on biologic immunogenicity.
• Analysis of immune system recognition pathways for biologics.
• Investigation of various nanotechnology applications for ADA mitigation.

Main Results:

• Understanding ADA formation is crucial for managing biologic therapies.
• Nanotechnology presents diverse approaches to control immune responses to biologics.
• These strategies hold potential for improved drug efficacy and patient safety.

Conclusions:

• Addressing immunogenicity is key to maximizing biologic therapy benefits.
• Nanotechnology offers innovative solutions to overcome ADA challenges.
• Further research in nanotech-based immunomodulation can advance biologic drug development.